Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the …